|
|
|
|
Animal Model >> null >> M_NLGN3_26_KI_R451C_HU-210 Construct Details |
| Model Details :M_NLGN3_26_KI_R451C_HU-210
|
| |
|
Model Type |
RESCUE-Pharmaceutical
|
|
Model Genotype |
Hemizygous
|
|
Mutation |
Mice harboring the mutation of CGT (arginine 451) to TGC (cysteine 451) in exon 7 were treated with CB1 receptor agonist HU-210 (1 microM, 20 min), as retrograde endocannabinoid signaling, acting through presynaptic CB1 receptors, is a well-established requirement for LTD expression and the authors sought to investigate the integrity and functional activity of CB1 receptor function in striatal neurons of R451C-NL3 mice. |
|
Allele Type |
ASD LOF mutation |
|
Strain of Origin |
(129X1/SvJ x 129S1/Sv)F1-Kitl+ |
|
Genetic Background |
B6*129 |
|
ES Cell Line |
Not Specified |
|
Mutant ES Cell Line |
Not Specified |
|
Model Source |
Sudhof laboratory (PMID 17823315 ) |
|
Reference |
Martella G , et al. 2017
|
|
|
